IL2 and multiple sclerosis: Additionally, MTO is approved to treat different forms of multiple sclerosis as it presents immunosuppressive activity such as the inhibition of B-cell, T-cell and macrophage proliferation and a decrease in the secretion of tumor necrosis factor alpha (TNF-α) and interleukin-2 (IL-2) [19].